Chinese Pharma Cracking The U.S. Market Via Reverse Mergers Draw Attention From Authorities
This article was originally published in PharmAsia News
HONG KONG - A number of Chinese companies publicly traded in the U.S., including several in the pharmaceutical space, have come under the spotlight in the last 18 months after getting to market through reverse mergers
You may also be interested in...
On the heels of ShangPharma, 3SBio’s move highlights depressed valuation for Chinese companies. The large premium should seal the deal for the company with a growing pipeline and revenues, analysts say.
China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.
Facing Potential Shareholder Suit And SEC Inquiry In U.S., China Sky One Medical Tries To Reassure Investors
BEIJING - While facing a potential shareholders' suit for possible violation of U.S. laws, the leadership of China Sky One Medical Inc. sought to reassure investors by disclosing a rise in earnings for 2010 and inviting investors to visit the firm's headquarters in Harbin, an ice-covered Chinese city that borders Russia's Siberia